Trial · NCT07877441
Antioxidant Supplementation and Muscle Recovery From DOMS in Trained Women
NCT07877441, Not applicable, Completed, Antonio Molina Lopez
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Antioxidant Supplementation and Muscle Recovery From DOMS in Trained Women. Trials, record NCT07877441. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07877441
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Antioxidant Supplementation and Muscle Recovery From DOMS in Trained Women
- NCT number
- NCT07877441
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 60 participants, actual
- Lead sponsor
- Antonio Molina Lopez
- Conditions
- Delayed Onset Muscle Soreness, Exercise-induced Muscle Damage, Muscle Recovery
- Interventions
- Creatine Monohydrate, Omega 3 FA (Fish Oil), N-Acetyl Cysteine (NAC), Coenzyme Q10 100 MG Oral Capsule, Placebo
- First posted
- 2026-10-16
- Last updated
- 2026-10-16
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Countermovement Jump Height (CMJ) | Baseline (Day 0), immediately post-exercise (Day 2), 24 hours after exercise (Day 3), 48 hours after exercise (Day 4), and 72 hours post-eccentric exercise (Day 5) | Assessed using My Jump Lab app (240 fps). Jump height in centimeters as indicator of lower limb neuromuscular performance recovery |
| Primary | Muscle Pain Pressure Threshold | Baseline (Day 0), immediately post-exercise (Day 2), 24 hours after exercise (Day 3), 48 hours after exercise (Day 4), and 72 hours post-eccentric exercise (Day 5) | Assessed using a pressure algometer (BASELINE). Measures the minimum pressure at which the participant perceives pain, expressed in kg/cm² |
| Primary | 30- Meter Sprint Time | Baseline (Day 0), immediately post-exercise (Day 2), 24 hours after exercise (Day 3), 48 hours after exercise (Day 4), and 72 hours post-eccentric exercise (Day 5) | Assessed using Witty photocell system (Microgate). Time in seconds to complete a 30-meter sprint. |
| Primary | Creatine Kinase (CK) | Baseline (Day 0), immediately post-exercise (Day 2), 24 hours after exercise (Day 3), 48 hours after exercise (Day 4), and 72 hours post-eccentric exercise (Day 5) | ssessed using SimplexTAS 101 analyzer. Serum CK activity in U/L as a biochemical marker of muscle damage. |
| Secondary | RIGHT LEG DYNAMOMENTRY | Baseline (Day 0), immediately post-exercise (Day 2), 24 hours after exercise (Day 3), 48 hours after exercise (Day 4), and 72 hours post-eccentric exercise (Day 5) | Assessed using Activforce 2 dynamometer. Maximum isometric knee extension force in kg. |
| Secondary | LEFT LEG DYNAMOMETRY | Baseline (Day 0), immediately post-exercise (Day 2), 24 hours after exercise (Day 3), 48 hours after exercise (Day 4), and 72 hours post-eccentric exercise (Day 5) | Assessed using Activforce 2 dynamometer. Maximum isometric knee extension force in kg. |
| Secondary | Thermography | Baseline (Day 0), immediately post-exercise (Day 2), 24 hours after exercise (Day 3), 48 hours after exercise (Day 4), and 72 hours post-eccentric exercise (Day 5) | Assessed using FLIR T2 A315 thermographic camera. Skin temperature of the quadriceps region in degrees Celsius as marker of local inflammation. |
| Secondary | Heart Rate Variability | Baseline (Day 0), immediately post-exercise (Day 2), 24 hours after exercise (Day 3), 48 hours after exercise (Day 4), and 72 hours post-eccentric exercise (Day 5) | Assessed using Polar Team Pro chest straps. 5-minute supine recording with eyes closed and deep breathing. Root mean square of successive differences in ms as autonomic recovery indicator. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07877441
GET https://conductscience.org/api/trials/v1/NCT07877441/registered